TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33011923

Group type: EXPERIMENTAL
Intervention: Insulin degludec 100 units/mL, given once daily after switching from other basal insulins
Number of subjects: 459
Study: 33012283

Group type: EXPERIMENTAL
Intervention: High-temporal-resolution PC-CMR
Number of subjects: 179

Group type: COMPARATOR
Intervention: Doppler ultrasound
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: PC-CMR acquisitions
Number of subjects: 179
Study: 33012343

Group type: EXPERIMENTAL
Intervention: Cell therapy (CD34)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 133
Study: 33012365

Group type: EXPERIMENTAL
Intervention: Pharmacotherapies for Alcohol Use Disorder
Number of subjects: 0
Study: 33012607

Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination introduced in 2013
Number of subjects: 2315
Study: 33012663

Group type: EXPERIMENTAL
Intervention: Using decision rules for removing outliers from FFQ data
Number of subjects: 181

Group type: COMPARATOR
Intervention: Not removing outliers
Number of subjects: 181
Study: 33012782

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg Q2W) + Gefitinib (250 mg QD)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Durvalumab and gefitinib in combination
Number of subjects: 56

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 56
Study: 33013294

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 37
Study: 33013302

Group type: EXPERIMENTAL
Intervention: 12 weeks sound therapy using adjusted narrow band sound
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy control group (HC)
Number of subjects: 27
Study: 33013517

Group type: EXPERIMENTAL
Intervention: TRT/EMDR
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRT/CBT
Number of subjects: 0
Study: 33013558

Group type: EXPERIMENTAL
Intervention: Standard polychromatic blue-enriched white light (7000 K; ∼200 lx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warm white light (2500 K)
Number of subjects: 0
Study: 33014426

Group type: EXPERIMENTAL
Intervention: 12-week exergaming (Jintronix®) telerehabilitation intervention
Number of subjects: 10
Study: 33014443

Group type: EXPERIMENTAL
Intervention: Therapeutic Hyper-CL™ lens
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard bandage contact lens (PureVision B&L)
Number of subjects: 49
Study: 33014774

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33014832

Group type: EXPERIMENTAL
Intervention: Multiple blood-brain barrier disruptions with Temozolomide
Number of subjects: 0
Study: 33015088

Group type: EXPERIMENTAL
Intervention: Chemotherapy in well-nourished patients
Number of subjects: 93

Group type: COMPARATOR
Intervention: Chemotherapy in malnourished patients
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Chemotherapy-related toxicity
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Survival at 6 months
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Number of hospitalizations
Number of subjects: 93
Study: 33015104

Group type: EXPERIMENTAL
Intervention: Vaginal Lactoferrin administration
Number of subjects: 0
Study: 33015171

Group type: EXPERIMENTAL
Intervention: Critical care ultrasound (CCUS)
Number of subjects: 181
Study: 33015525

Group type: EXPERIMENTAL
Intervention: Dickkopf-1 (DKK1) targeting in clinical trial (NCT03837353)
Number of subjects: 0
Study: 33015640

Group type: EXPERIMENTAL
Intervention: Telemedicine-delivered weight-loss program
Number of subjects: 27
Study: 33015643

Group type: EXPERIMENTAL
Intervention: IFX-1 (vilobelimab)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Best supportive care (control)
Number of subjects: 30
Study: 33016100

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (S/V) treatment
Number of subjects: 782
Study: 33016805

Group type: EXPERIMENTAL
Intervention: Endovascular treatment for symptomatic PAD
Number of subjects: 0
Study: 33016887

Group type: EXPERIMENTAL
Intervention: Mobile app exercise intervention
Number of subjects: 28
Study: 33016924

Group type: EXPERIMENTAL
Intervention: mRNA vaccine
Number of subjects: 4
Study: 33017106

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (10-day course)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 1552
Study: 33017497

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg IV, day 1 every 2 weeks) plus FOLFOX4
Number of subjects: 8
Study: 33017533

Group type: EXPERIMENTAL
Intervention: Manipulated HRV tracings with up to 5 beats selected at the wrong time interval and up to 36% of BBIs removed.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manipulated HRV tracings with up to 3 beats selected at the wrong time interval and up to 36% of BBIs removed.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Manipulated HRV tracings with more than 2 beats selected at the wrong time interval and any BBIs removed.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Time domain HRV metrics.
Number of subjects: 10
Study: 33017652

Group type: EXPERIMENTAL
Intervention: meta-GAM method for meta-analysis of generalized additive models
Number of subjects: 0
Study: 33017671

Group type: COMPARATOR
Intervention: Stopwatch (Ultrak chronometer®)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Electronic walkway (Zeno Mat®)
Number of subjects: 34
Study: 33020153

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 0
Study: 33020163

Group type: EXPERIMENTAL
Intervention: Bioanalysis method for predicting unbound ceftriaxone concentrations
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Three predictive equations (empirical)
Number of subjects: 92
Study: 33020485

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study: 33020594

Group type: EXPERIMENTAL
Intervention: TAS-119 (200 mg BID, 4 days on/3 days off, 3 out of 4 weeks)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: TAS-119 (150, 200, 250, 300 mg BID)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: TAS-119
Number of subjects: 74
Study: 33020819

Group type: EXPERIMENTAL
Intervention: Screen-detected atrial fibrillation (AF)
Number of subjects: 7107

Group type: COMPARATOR
Intervention: Normal ECG (Control)
Number of subjects: 7107

Group type: EXPERIMENTAL
Intervention: Screen-detected AF
Number of subjects: 7107

Group type: EXPERIMENTAL
Intervention: Newly diagnosed AF
Number of subjects: 7107

Group type: EXPERIMENTAL
Intervention: Known AF
Number of subjects: 7107
Study: 33020924

Group type: EXPERIMENTAL
Intervention: DPYD-guided dose-individualization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of DPD enzyme activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of pretreatment endogenous serum uracil concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uracil/dihydrouracil-ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FU degradation rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacokinetically guided follow-up of 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (sex, age, body composition, renal function)
Number of subjects: 0
Study: 33021490

Group type: EXPERIMENTAL
Intervention: Information and communication technology-enhanced integration of health and social care (intervention)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Basic health and social care coordination (comparator)
Number of subjects: 198
Study: 33021640

Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Zein
Number of subjects: 22

Group type: COMPARATOR
Intervention: Protein-free group
Number of subjects: 22
Study: 33021843

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33021872

Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR T-cell therapy (FMC63-28Z)
Number of subjects: 43
Study: 33021869

Group type: EXPERIMENTAL
Intervention: COVID-19-free surgical pathways
Number of subjects: 9171

Group type: COMPARATOR
Intervention: No defined pathway
Number of subjects: 9171
Study: 33022004

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2378

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 2378
Study: 33022066

Group type: EXPERIMENTAL
Intervention: Zanubrutinib (BGB-3111) plus obinutuzumab
Number of subjects: 81
Study: 33022101

Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation (DBS)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Dopamine agonist dose reduction
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Preoperative dyskinesias
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Baseline apathy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Postoperative apathy
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Stimulation power and position of active contacts
Number of subjects: 217
Study: 33022316

Group type: COMPARATOR
Intervention: Physically active men (White NHs)
Number of subjects: 44953

Group type: COMPARATOR
Intervention: Physically active men (Black NHs)
Number of subjects: 44953

Group type: COMPARATOR
Intervention: Physically active men (Asian NHs)
Number of subjects: 44953

Group type: COMPARATOR
Intervention: Physically active women (White NHs)
Number of subjects: 44953

Group type: COMPARATOR
Intervention: Physically active women (Hispanics)
Number of subjects: 44953
Study: 33022376

Group type: EXPERIMENTAL
Intervention: UM171-expanded CB transplant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmanipulated CB transplant
Number of subjects: 0
Study: 33022752

Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 3282

Group type: COMPARATOR
Intervention: Environmental interventions (Dust control)
Number of subjects: 3282

Group type: COMPARATOR
Intervention: Soil abatement
Number of subjects: 3282

Group type: COMPARATOR
Intervention: Combination of educational and environmental interventions
Number of subjects: 3282
Study: 33022852

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 252
Study: 33023304

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33023522

Group type: EXPERIMENTAL
Intervention: Young group (ages 20-39 years)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Middle-aged group (ages 40-59 years)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Older group (aged ≥60 years)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 209
Study: 33023562

Group type: EXPERIMENTAL
Intervention: Baseline stress, anxiety, and depression
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Household income <$50,000
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Household income ≥$100,000
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Women who lost household income
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 356
Study: 33023763

Group type: EXPERIMENTAL
Intervention: Binge Eating Disorder (BED) subjects
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-BED subjects
Number of subjects: 101
Study: 33023948

Group type: EXPERIMENTAL
Intervention: XPO1 inhibitors (selinexor, eltanexor, KOS-2464) combined with melphalan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent melphalan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selinexor with melphalan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XPO1 inhibitors (selinexor, eltanexor) with melphalan
Number of subjects: 0
Study: 33023952

Group type: EXPERIMENTAL
Intervention: Neoadjuvant enzalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Neoadjuvant enzalutamide plus ADT
Number of subjects: 39
Study: 33023999

Group type: EXPERIMENTAL
Intervention: Masimo Radical-7
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Apple iPhone 6S
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Samsung S8
Number of subjects: 47
Study: 33024146

Group type: EXPERIMENTAL
Intervention: Callascope (self-imaging)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Callascope (clinician-based imaging)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Post-exam surveys (Callascope)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard-of-care speculum exam
Number of subjects: 75
Study: 33024564

Group type: EXPERIMENTAL
Intervention: Flywheel (FW) squats
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bodyweight Free (BFW) squats
Number of subjects: 38
Study: 33024581

Group type: EXPERIMENTAL
Intervention: NESS-EFTR with sentinel basin dissection
Number of subjects: 20
Study: 33024925

Group type: EXPERIMENTAL
Intervention: omega-oil
Number of subjects: 272

Group type: COMPARATOR
Intervention: placebo control diets
Number of subjects: 272
Study: 33024987

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg once daily
Number of subjects: 151
Study: 33025093

Group type: EXPERIMENTAL
Intervention: Threshold-based contouring using GTV
Number of subjects: 9
Study: 33025213

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day for 3 weeks on, 1 week off)
Number of subjects: 34
Study: 33025282

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (GKRS)
Number of subjects: 92
Study: 33025378

Group type: EXPERIMENTAL
Intervention: IgPro20 manual push infusion at 0.5 mL/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IgPro20 manual push infusion at 1.0 mL/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IgPro20 manual push infusion at 2.0 mL/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall tolerability across all flow rates
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serum IgG levels at study start
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serum IgG levels at study end
Number of subjects: 16
Study: 33025409

Group type: EXPERIMENTAL
Intervention: Chlorhexidine dressing
Number of subjects: 50
Study: 33025481

Group type: EXPERIMENTAL
Intervention: Black carbon dye tattooing of biopsied axillary node (2.0 ml median volume injected, range 0.2-4.2 ml)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Primary surgery group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NACT with SNB
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NACT with ALND
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NACT group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Timing between dye injection and surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Body mass index
Number of subjects: 110

Group type: COMPARATOR
Intervention: Volume of dye injected
Number of subjects: 110
Study: 33025482

Group type: EXPERIMENTAL
Intervention: Eribulin as first- or second-line therapy
Number of subjects: 83
Study: 33025545

Group type: EXPERIMENTAL
Intervention: Serial simplified electrophysiological assessment of the unilateral common peroneal nerve and the sural nerve, performed minimally on alternate days after baseline evaluation.
Number of subjects: 97
Study: 33025558

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Simulation model
Number of subjects: 1345
Study: 33025707

Group type: EXPERIMENTAL
Intervention: L-leucine 700 mg/m
Number of subjects: 55
Study: 33025716

Group type: EXPERIMENTAL
Intervention: 200 mg erythromycin infused intravenously over 20 min
Number of subjects: 6
Study: 33026184

Group type: EXPERIMENTAL
Intervention: High-risk arm protocol therapy
Number of subjects: 123
Study: 33026291

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pain + Activity
Number of subjects: 14
Study: 33026463

Group type: EXPERIMENTAL
Intervention: Maternal type 1 diabetes
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: Paternal type 1 diabetes
Number of subjects: 2074

Group type: COMPARATOR
Intervention: Sibling with type 1 diabetes
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: Height velocity (z score/year) in the first 24 months
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: Birthweight
Number of subjects: 2074
Study: 33026630

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA nonresponders
Number of subjects: 1384
Study: 33026631

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 1384
Study: 33026753

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution, administered once daily for 48 weeks
Number of subjects: 62
Study: 33026772

Group type: EXPERIMENTAL
Intervention: Halobetasol propionate 0.01%/Tazarotene 0.045% lotion (HP/TAZ)
Number of subjects: 1
Study: 33026892

Group type: EXPERIMENTAL
Intervention: Telemetric ECG monitoring
Number of subjects: 140

Group type: COMPARATOR
Intervention: Not applicable (control group: discharged patients)
Number of subjects: 140
Study: 33026965

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study: 33027064

Group type: EXPERIMENTAL
Intervention: K-means MTV 2-clusters (MTVhi, MTVlo)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MTVlo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MTVhi
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MTV/MTV cluster regions
Number of subjects: 25
Study: 33027067

Group type: EXPERIMENTAL
Intervention: Firibastat (RB150/QGC001)
Number of subjects: 0
Study: 33027186

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive group
Number of subjects: 991

Group type: COMPARATOR
Intervention: SARS-CoV-2 negative group
Number of subjects: 991
Study: 33027187

Group type: EXPERIMENTAL
Intervention: Fungal sensitization in asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antifungals and targeted biologic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 33027199

Group type: EXPERIMENTAL
Intervention: Fitting to Outcome eXpert (FOX) programming
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional programming methods (Nucleus CI532 trial)
Number of subjects: 31
Study: 33027243

Group type: EXPERIMENTAL
Intervention: Rhinovirus positive
Number of subjects: 163

Group type: COMPARATOR
Intervention: Rhinovirus negative
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Virus positive
Number of subjects: 163

Group type: COMPARATOR
Intervention: Virus negative
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Mild upper respiratory complaints reported by parents
Number of subjects: 163
Study: 33027260

Group type: EXPERIMENTAL
Intervention: Modified HEART Pathway and point-of-care troponin testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 0
Study: 33027294

Group type: EXPERIMENTAL
Intervention: Vibration perception threshold (VPT) measured using a biothesiometer on big toes, insteps, lateral malleoli, and wrists
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Regression equations for calculating age- and height-specific normal values for VPT
Number of subjects: 205
Study: 33027528

Group type: EXPERIMENTAL
Intervention: NHL-like regimens followed by allogeneic HSCT
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: AL-like regimens without consolidation
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: NHL-like regimens without consolidation
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Chemotherapy with lymphoma- or AL-like regimens followed by transplantation
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Consolidation with allogeneic HSCT
Number of subjects: 398
Study: 33027564

Group type: EXPERIMENTAL
Intervention: Exome sequencing for detecting genetic variants classified as pathogenic or likely pathogenic
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Exome sequencing
Number of subjects: 127
Study: 33027844

Group type: EXPERIMENTAL
Intervention: Retrievable inferior vena caval filter plus anticoagulation
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Filter
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 1388
Study: 33028076

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin, bendamustine and rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33028098

Group type: EXPERIMENTAL
Intervention: u-hscTnI (ultra-high-sensitivity cardiac troponin I) measurements
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Logistic regression models adjusted for traditional cardiovascular risk factors
Number of subjects: 263
Study: 33028169

Group type: EXPERIMENTAL
Intervention: Prolonged release budesonide granules (9 mg daily for 8 weeks)
Number of subjects: 61
Study: 33028221

Group type: EXPERIMENTAL
Intervention: Targeted Hypothermia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Targeted Normothermia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matched control group of acute myocardial infarction (MI) patients
Number of subjects: 100
Study: 33028346

Group type: EXPERIMENTAL
Intervention: Short-course radiation followed by 6 cycles of mFOLFOX6 plus avelumab (10 mg/kg) every 2 weeks for 6 cycles.
Number of subjects: 44
Study: 33028594

Group type: EXPERIMENTAL
Intervention: Hypervascular cellular habitat
Number of subjects: 97